Skip to main content
. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373

Figure 3.

Figure 3

Genomic features of the tumor immune microenvironment. (A) Violin plots of tumor mutation burden for SCLC tumors of the present study (n = 85) and for the top 10 and bottom 10 LUAD tumors in TCGA ranked according to TMB. The p values were determined with Dunn’s test, with statistical significance defined as a p value of less than 0.025. (B) Kaplan-Meier curves for progression-free survival according to TMB in the ICI combo-cohort of patients with SCLC. Patients were split into high (≥median) and low (<median) TMB groups. (C) Violin plots for the absolute counts of fs-indels in SCLC tumors of the present study (n = 85) and in the top 10 and bottom 10 LUAD tumors in TCGA ranked according to TMB. The p values were determined with Dunn’s test, with statistical significance defined as a p value of less than 0.025. (D) Violin plots for the proportion of fs-indels in SCLC and LUAD as in (C). (E) Kaplan-Meier curves for progression-free survival according to predicted frameshift neoantigen load in the ICI combo-cohort of patients with SCLC. Patients were split into high (≥median) and low (<median) load groups. CI, confidence interval; fs-indels, frameshift insertions and deletions; HR, hazard ratio; ICI, immune checkpoint inhibitor; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; TMB, tumor mutation burden.